GlaxoSmithKline logo

Patient group funding

European Organisation for Rare Diseases (Eurordis)

Eurordis is a patient-driven alliance of patient organisations and individuals active in the field of rare diseases.

Eurordis’ mission is to build a strong pan-European community of patient organisations and people living with rare diseases, to be their voice at the European level, and - directly or indirectly - to fight against the impact of rare diseases on their lives.

We have supported this organisation since 2006.

During 2010:

  • We gave an unrestricted grant of €10000 to become a member of the round table of companies. This was created to establish a long-term educational relationship between Eurordis and companies that have an interest in orphan drug development.
  • We gave an educational grant of €5000 to help support the organisation of the 5th European Conference on Rare Diseases ECRD in Krakow, Poland.  

Our funding represents around 0.42% of their income overall.



During 2009:

  • We gave an unrestricted grant of €10000 to become a member of the round table of companies. This was created to establish a long-term educational relationship between Eurordis and companies that have an interest in orphan drug development.
  • Also we gave an educational grant of €5000 to support the organisation of Eurordis Membership meeting on 8 and 9 May in Athens. 


During 2008:

  • We gave an unrestricted grant €10,000 to become a member of the round table of companies. This was created to establish a long-term educational relationship between Eurordis and companies that have an interest in orphan drug development.
  •  In addition we gave an educational grant of €5000 to help support the Eurordis annual membership meeting held in Copenhagen in May. 

During 2007:

  • We gave an unrestricted grant of €10,000 to become a member of the round table of companies. This was created to establish a long-term educational relationship between Eurordis and companies that have an interest in orphan drug development.  
  •  In addition we gave an educational grant of €1000 to help support the Eurordis annual membership meeting. 

Our funding represents around 0.4% of their income overall.



In 2006:

  • We gave an unrestricted grant of €10,000 to become a member of the round table of companies. This was created to establish a long-term educational relationship between Euordis and companies that have an interest in orphan drug development.
Our funding represents less than 1% of their income overall.